Plus Therapeutics Stock Today
| PSTV Stock | USD 1.17 0.02 1.68% |
Performance0 of 100
| Odds Of DistressOver 85
|
Plus Therapeutics is selling for under 1.17 as of the 18th of January 2025; that is 1.68 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.16. Plus Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of November 2000 | Category Healthcare | Classification Health Care |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. The company has 5.9 M outstanding shares of which 113.44 K shares are at this time shorted by private and institutional investors with about 0.98 trading days to cover. More on Plus Therapeutics
Moving together with Plus Stock
Moving against Plus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Plus Stock Highlights
| CEO President | MD MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPlus Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Plus Therapeutics' financial leverage. It provides some insight into what part of Plus Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Plus Therapeutics (PSTV) is traded on NASDAQ Exchange in USA. It is located in 4200 Marathon Boulevard, Austin, TX, United States, 78756 and employs 20 people. Plus Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.02 M. Plus Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 5.9 M outstanding shares of which 113.44 K shares are at this time shorted by private and institutional investors with about 0.98 trading days to cover.
Plus Therapeutics currently holds about 20.27 M in cash with (12.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6.
Check Plus Therapeutics Probability Of Bankruptcy
Ownership AllocationRoughly 86.36 pct. of Plus Therapeutics outstanding shares are held by general public with 2.34 % owned by insiders and only 11.3 (%) by third-party entities.
Check Plus Ownership Details
Plus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citadel Advisors Llc | 2024-09-30 | 0.0 | |
| Renaissance Technologies Corp | 2024-06-30 | 0.0 | |
| Aigh Capital Management, Llc | 2024-09-30 | 560.9 K | |
| Geode Capital Management, Llc | 2024-09-30 | 54.3 K | |
| Vanguard Group Inc | 2024-09-30 | 32.5 K | |
| Blackrock Inc | 2024-09-30 | 7 K | |
| Tower Research Capital Llc | 2024-09-30 | 3.7 K | |
| Advisor Group Holdings, Inc. | 2024-09-30 | 133 | |
| Jpmorgan Chase & Co | 2024-09-30 | 100.0 | |
| Bank Of America Corp | 2024-09-30 | 48.0 | |
| Group One Trading, Lp | 2024-09-30 | 1.0 |
Plus Therapeutics Historical Income Statement
Plus Stock Against Markets
Plus Therapeutics Corporate Management
| John Fraser | Chief Scientist | Profile | |
| Gary CPA | Advisor | Profile | |
| MS MBA | New Strategy | Profile | |
| Marc MD | CEO Pres | Profile | |
| Desiree Smith | Principal Controller | Profile | |
| Andrew Sims | VP CFO | Profile |
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.